Table 1.
Proportion of different MET alterations in NSCLC patients.
| MET Alterations | Proportion, % | Publication [Reference] | |
|---|---|---|---|
| METex14 | NSCLC 1 | 0.9–4 | Davies KD et al. [6] |
| PSC subtype | 20–31.8 | Mo HN et al. [15] Tong JH et al. [16] |
|
| MET Fusion 1 | 0.5 | Recondo G et al. [18] | |
| MET Overexpression 1 | 13.7–63.7 | Guo R et al. [17] | |
| MET Amplification 2 | 1–5 | Guo R et al. [17] | |
| Secondary MET Amplification | 1/2G EGFR–TKI resistance | 5–22 | Recondo G et al. [18] Bean J et al. [21] |
| 3G EGFR–TKI resistance | 5–50 | Wang Y et al. [22] | |
| MET Amplification Co-occurrence with EGFR Mutation 3 | 2–11 | Li XM et al. [23] Lai GGY et al. [24] |
|
1 Based on overall NSCLC population. 2 Based on treatment-naïve NSCLC population. 3 Based on EGFR-positive treatment-naïve NSCLC population. EGFR, Epidermal Growth Factor Receptor; TKI, Tyrosine Kinase Inhibitor; MET, Mesenchymal Epithelial Transition; NSCLC, Non-Small Cell Lung Cancer; PSC, Pulmonary Sarcomatoid Carcinoma.